Editor’s highlights from Future Oncology – February 2021

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares some of his top picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis’ highlights below: The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. The LEAP program is a broad series of three Phase II and nine Phase III clinical trials covering several cancers and settings, specifically where there is greater need for new treatment options. The development of the program followed results of the ongoing KEYNOTE-146 and...